Do you use the clozapine or norclozapine plasma concentration to assess efficacy?

Use Clozapine Levels, Not Norclozapine, for Assessing Efficacy

Monitor clozapine plasma concentrations—not norclozapine—to guide dose titration and assess therapeutic response. The most recent international guidelines and FDA labeling consistently reference clozapine levels alone when establishing therapeutic targets 1.

Guideline-Based Therapeutic Targets

The 2025 INTEGRATE guidelines provide explicit clozapine concentration targets 1:

• Initial target: ≥350 ng/mL if therapeutic response is not achieved at lower concentrations
• Escalation range: up to 550 ng/mL if positive symptoms persist after 12 weeks at therapeutic levels
• Above 550 ng/mL: Number needed to treat is 17, with increased seizure risk—requires shared decision-making and prophylactic lamotrigine consideration

Notably, these guidelines make no mention of norclozapine levels or ratios when discussing efficacy monitoring.

Why Norclozapine Is Not Used for Efficacy Assessment

The FDA label explicitly states that norclozapine (N-desmethylclozapine) has "only limited activity" while hydroxylated and N-oxide derivatives are inactive 2. This pharmacological reality explains why:

• Research consistently shows clozapine concentrations correlate with clinical response, while norclozapine levels do not 3, 4
• A 2000 study found mean clozapine levels were significantly higher in responders (472 vs 328 ng/mL, P<0.01), but norclozapine levels did not differ between responders and non-responders 4
• The optimal cutoff of 350-400 ng/mL applies to clozapine alone 4

What About the Clozapine:Norclozapine Ratio?

The clozapine:norclozapine ratio provides information about drug clearance and metabolism, not efficacy 5, 6:

• A ratio ≥2 suggests saturation of clozapine metabolism 7
• The ratio helps identify drug interactions (e.g., valproate increases the ratio by 76%) 6
• The ratio does not predict treatment response or need for augmentation 6
• Recent 2026 data confirms CLZ/NCLZ is not linked to metabolic outcomes or treatment response 6

Common Pitfalls to Avoid

1. Don't target norclozapine levels—laboratories report them automatically, but they don't guide dosing
2. Don't use the ratio to assess efficacy—it reflects metabolism, not therapeutic effect
3. Don't assume higher ratios mean better response—no evidence supports this 6
4. Sex differences matter: Females achieve significantly higher clozapine concentrations at equivalent doses, requiring more cautious titration 8

Practical Algorithm

When therapeutic drug monitoring shows:

• Clozapine <350 ng/mL with inadequate response → Increase dose
• Clozapine 350-550 ng/mL with inadequate response → Consider 12-week trial at this range before further escalation 1
• Clozapine >550 ng/mL → Diminishing returns; consider augmentation strategies instead 1
• Abnormal clozapine:norclozapine ratio → Investigate drug interactions or adherence issues, not efficacy 5

The 2026 dose-response meta-analysis identified exploratory turning points for efficacy around 535-898 ng/mL, but emphasized these should not be interpreted as universal targets for dose escalation 9. Individual therapeutic drug monitoring remains essential, but clozapine concentration alone drives dosing decisions.